Is AOD-9604 Legal in Massachusetts? What Women Need to Know Before Buying

What AOD-9604 Actually Is

AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (hGH), corresponding to residues 176-191 of the hGH C-terminus. Researchers originally hoped it would reproduce the fat-metabolism effects of hGH without the insulin-resistance and IGF-1-driven side effects tied to the full molecule.

The compound works by stimulating lipolysis (the breakdown of stored fat) and inhibiting lipogenesis (the formation of new fat cells) through beta-adrenergic receptors. It does not appear to raise IGF-1 levels at the doses studied, which was the theoretical safety advantage over full hGH.

The Clinical Evidence Is Thin and Old

The most cited evidence comes from a small Phase II/III trial (METAOD001) conducted in Australia in 2001, which found modest weight loss in adults with obesity over 12 weeks. That trial enrolled approximately 300 participants. There has been no large, well-powered, peer-reviewed randomized controlled trial published since. The compound's developer, Metabolic Pharmaceuticals, applied to the Australian Therapeutic Goods Administration (TGA) but ultimately did not achieve approval.

No trial has specifically enrolled women across reproductive life stages, women with PCOS, perimenopausal women, or postpartum women. That is a significant evidence gap, and it matters because body composition, fat distribution, and metabolic rate shift substantially across a woman's hormonal life.

Why Women Are Targeted

AOD-9604 is aggressively marketed toward women seeking weight loss, particularly those who feel they have "tried everything." Women with PCOS, who carry excess visceral fat partly because of hyperinsulinemia and androgen excess, are a frequent marketing target. Perimenopausal women, who experience a documented shift in fat distribution from peripheral to visceral as estrogen declines, are also heavily targeted. There is no published clinical evidence that AOD-9604 addresses either of these specific hormonal drivers.

The Federal Legal Framework: Why the Gray Zone Exists

The federal framework is where the real legal complexity lives, and it directly controls what any Massachusetts pharmacy or prescriber can legally do.

FDA Approval Status

AOD-9604 has never received FDA approval as a finished drug product in the United States for any indication. Without FDA approval, a drug cannot be manufactured commercially and sold through ordinary retail or online pharmacies.

The 503A and 503B Compounding Pharmacy Rules

Compounding pharmacies operate under either Section 503A of the Federal Food, Drug, and Cosmetic Act (small-batch, patient-specific compounding) or Section 503B (larger-scale outsourcing facilities). Both pathways have rules about which bulk drug substances they can use.

The FDA maintains a list of bulk drug substances that are under evaluation or nominated for compounding. AOD-9604 appears on the FDA's Bulks List for 503A pharmacies as a substance of concern, meaning it has been nominated but placed in a category where compounding is not currently permitted while the FDA completes its review. A 503A pharmacy that compounds AOD-9604 is operating outside federal law. The same restriction applies under the 503B outsourcing facility framework.

This federal prohibition does not require a separate Massachusetts state law to take effect. Federal law preempts the field here.

Is It a Controlled Substance?

No. AOD-9604 is not scheduled under the Controlled Substances Act. It is not a Schedule I, II, III, IV, or V substance. This is a critical distinction. Being "not controlled" does not mean it is legal to sell or compound. It means only that possession by an individual is not a federal drug crime in the same way that possession of fentanyl or alprazolam without a prescription would be.

The enforcement mechanism for AOD-9604 runs through the FDA's drug approval and compounding frameworks, not through DEA scheduling.

Massachusetts State Law: What the Commonwealth Actually Says

Massachusetts does not have a statute that independently bans or specifically regulates AOD-9604 by name. State law in this area is primarily channeled through three bodies: the Massachusetts Board of Registration in Pharmacy, the Board of Registration in Medicine, and the general consumer protection laws enforced by the Attorney General's office.

The Massachusetts Board of Registration in Pharmacy

Massachusetts pharmacies and pharmacists are licensed and regulated by the Board of Registration in Pharmacy. The Board requires pharmacies to comply with federal law, including FDA regulations on compounding. A Massachusetts compounding pharmacy that compounds AOD-9604 would be in violation of federal compounding law, which the Board can act on through its own disciplinary authority. The practical result is the same: no licensed Massachusetts compounding pharmacy can legally produce AOD-9604 for dispensing to patients.

The Board of Registration in Medicine

Physicians and nurse practitioners in Massachusetts are licensed through the Board of Registration in Medicine. Writing a prescription for a drug that cannot be legally compounded or dispensed does not automatically constitute a criminal act by the prescriber, but it does create a prescription that no licensed pharmacy can fill. Prescribers who recommend patients obtain AOD-9604 from online gray-market or overseas sources may face professional conduct review.

Online and Gray-Market Sources

Here is the practical reality many marketing sites obscure. When you see AOD-9604 sold online as a "research chemical," it is typically labeled "for research use only, not for human use." These products are not manufactured under FDA oversight, have no verified potency or purity standards, and importing them for personal use sits in a legally ambiguous space the FDA has historically tolerated but retains the right to act on at any time.

Buying AOD-9604 from these sources is not a Massachusetts criminal offense in the way that buying heroin would be. But you have no guarantee of what is in the vial, no recourse if it causes harm, and no clinical relationship with a provider who can monitor you.

The clearest framework for understanding your actual legal risk as a woman in Massachusetts is this three-level distinction:

Level 1: Criminally illegal. AOD-9604 does not reach this level for personal possession. It is not a scheduled controlled substance.

Level 2: Legally blocked from licensed dispensing. AOD-9604 is here. No licensed Massachusetts pharmacy can legally compound or dispense it under current federal rules, regardless of whether you have a prescription.

Level 3: Regulated but accessible. FDA-approved drugs and legally compoundable peptides (such as certain formulations of semaglutide during a declared shortage, under specific FDA guidance) sit here. AOD-9604 does not.

This distinction matters because marketing language like "legal peptide" typically refers to Level 1 only, not Level 2. A woman reading that AOD-9604 is "not illegal" is being given a technically narrow statement that omits the more relevant regulatory barrier.

How to Get AOD-9604 in Massachusetts: The Honest Answer

You cannot legally obtain AOD-9604 through a licensed Massachusetts pharmacy or telehealth platform operating under federal compliance. Period. Any telehealth company or med-spa in Massachusetts offering AOD-9604 dispensed through their own compounding partner is operating outside current FDA compounding rules.

What Legitimate Prescribers Can Offer Instead

If your goal is weight loss, fat loss during perimenopause, or improving metabolic markers in PCOS, there are FDA-approved and legally compoundable options worth discussing with a licensed provider:

• Semaglutide (Ozempic, Wegovy): FDA-approved for weight management. During the declared shortage period, compounded versions were permitted; access has changed as shortage designations are updated. Ask your provider about current status.
• Tirzepatide (Zepbound): FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related comorbidity.
• Metformin: Off-label but widely used in PCOS for insulin sensitization, with decades of safety data including in premenopausal women.
• Tesamorelin: A growth hormone-releasing hormone analog that is FDA-approved (for HIV-associated lipodystrophy) and is on the FDA's 503A bulks list as permissible for compounding under specific conditions. It is not approved for general weight loss, but it has a clearer legal pathway than AOD-9604.

A WomanRx provider can review your goals, hormonal status, and metabolic markers to identify what is both legal and evidence-based for your life stage.

Who This Is Right For and Who It Is Not

Women for Whom This Discussion Is Relevant

You may be researching AOD-9604 because you are dealing with weight that has not responded to diet and exercise, and a search or social media post pointed you here. That experience is real and common. Women carry a higher body fat percentage than men at the same BMI partly because of estrogen's effect on adipose tissue distribution, and women lose fat mass more slowly than men on equivalent caloric deficits in multiple controlled trials.

If you are in perimenopause, your visceral fat is increasing even if your weight is stable, a phenomenon documented in the Study of Women's Health Across the Nation (SWAN). If you have PCOS, hyperinsulinemia drives fat storage in ways that calorie restriction alone often cannot override. These are real physiological needs that deserve real, evidence-backed solutions.

Women for Whom AOD-9604 Is Not Appropriate

• Pregnant women: There are no human safety data for AOD-9604 in pregnancy. The compound has no FDA pregnancy category because it has never been approved. Animal reproductive studies have not been published in peer-reviewed literature for this specific fragment. Do not use it.
• Women breastfeeding: No lactation transfer data exist. Because it is a peptide, some oral breakdown would occur if ingested by an infant through breast milk, but injectable exposure via milk is unpredictable. Avoid entirely.
• Women trying to conceive: No reproductive toxicology data in humans exist. Given the complete absence of safety data, using an unregulated peptide while trying to conceive is not a risk worth taking when legal, studied alternatives exist.
• Women with active cancer or a history of hormone-sensitive cancer: Growth hormone fragments carry a theoretical concern about stimulating IGF-1-independent growth pathways. The evidence is not established, but the absence of data in this population is a reason to avoid it.
• Women with disordered eating history: Peptides marketed for fat loss can reinforce harmful weight-focused behaviors. A provider who specializes in both metabolic health and eating disorder history should be consulted first.

Pregnancy, Lactation, and Contraception: The Full Picture

This section is required reading if you are at any stage of reproductive planning.

Pregnancy

AOD-9604 has no FDA pregnancy category because it has never been approved. No published human data on pregnancy outcomes following AOD-9604 exposure exists. The compound is a synthetic peptide administered by subcutaneous injection. Peptides can cross biological barriers, and without specific placental transfer data, the risk to a developing fetus cannot be characterized as either safe or definitively harmful. The standard pharmacological and ethical position in this situation is clear: do not use an unapproved compound with no pregnancy safety data during pregnancy.

If you became pregnant while using AOD-9604 from a gray-market source, disclose this to your OB-GYN immediately. The conversation should include whatever information you have about the source, concentration, and duration of use.

Lactation

No published data on AOD-9604 transfer into human breast milk exists. LactMed, the NIH's drug and lactation database, does not have an entry for AOD-9604, which itself reflects the complete absence of controlled data. Until such data exist, avoid use during breastfeeding.

Contraception Considerations

AOD-9604 is not a teratogen with a known mechanism in humans. There is no formal contraception requirement attached to it in the way that, for example, isotretinoin's iPLEDGE program requires for women of childbearing potential. Nevertheless, using any uncharacterized compound while not using effective contraception introduces an undefined risk. If you are of reproductive age and considering any unapproved peptide, discuss contraception with your provider as part of that conversation.

The Evidence Gap and What Honest Providers Should Tell You

Women have been under-represented in clinical trials across virtually every therapeutic area. A 2020 analysis in JAMA Internal Medicine found that women made up fewer than 40% of participants in cardiovascular drug trials despite representing the majority of cardiovascular deaths. The pattern repeats in metabolic research.

For AOD-9604 specifically, the evidence gap is even more stark. The primary published trial METAOD001 did not report sex-stratified results in detail. No trial has examined AOD-9604 in women with PCOS, perimenopausal women with metabolic syndrome, postpartum women with retained weight, or women on hormonal contraception. What this means practically: any claim that AOD-9604 produces a specific weight loss result in women is extrapolated from mixed-sex or unpublished data.

As the Endocrine Society's clinical practice guidelines on obesity pharmacotherapy note, weight management interventions must account for sex differences in pharmacokinetics, hormonal context, and comorbidities. AOD-9604 has not been studied in any of these contexts for women.

An honest provider will tell you this. A provider who offers AOD-9604 in Massachusetts through a compounding pharmacy without acknowledging the federal legal restriction or the evidence gaps is not giving you complete information.

What to Ask a Massachusetts Provider About Weight Management

If you are meeting with a telehealth provider, weight-loss clinic, or med-spa and AOD-9604 comes up, here are direct questions to ask:

1. Is the pharmacy you are using a licensed 503A or 503B facility, and how is it authorized to compound AOD-9604 given the current FDA bulks list status?
2. Can you show me published data specifically in women at my hormonal life stage supporting this treatment?
3. What monitoring will you do while I am using this compound?
4. What are the discontinuation protocols if I experience side effects?

If the provider cannot answer questions 1 and 2 clearly, that is a signal to seek a second opinion.